NRx Challenges Toxic Ketamine Preservative – Preservative-Free Innovation

Aug 13, 2025

For biotech investors and mental health treatment innovators: Jonathan Javitt, CEO of NRx Pharmaceuticals (NASDAQ: NRXP), explains why the company filed a citizen’s petition with the FDA to remove benzethonium chloride from ketamine products—an outdated preservative now linked to toxicity.

With the potential to be the only FDA-approved supplier of preservative-free ketamine, NRx could reshape a $750M market, providing safer options for patients and securing a strong competitive edge. Learn why this decision could change the landscape for depression, anesthesia, and other ketamine-based treatments.

💊 Ticker: NRXP
🌐 Learn More: nrxpharma.com

🏷️ Tags
#NRxPharmaceuticals #NRXP #KetamineTherapy #PreservativeFree #BenzethoniumChloride #DrugSafety #MentalHealthTreatment #FDApetition #BiotechInvesting #AnesthesiaInnovation #PharmaceuticalReform #DepressionTreatment #ToxicPreservatives #DryEyeResearch #FDACompliance #PharmaInnovation #CitizenPetition #NRxPharma #NewToTheStreet #MedicalBreakthrough #FDAReview #HealthPolicy